EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil

Tania F Cestari, Cacilda da Silva Souza, Luna Azulay-Abulafia, Ricardo Romiti, André V E Carvalho, Caio César Silva de Castro, Sílvio Alencar Marques, João Roberto Antonio, Lincoln Fabrício, Ahmed M Soliman, Tianshuang Wu, Ranjeeta Sinvhal und 5 weitere

Anais Brasileiros de Dermatologia · 2025

DOI: 10.1016/j.abd.2024.08.002 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Anais Brasileiros de Dermatologia, 2025. Verfasst von Tania F Cestari und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. Electronic addr…. Hauptthemen laut MEDLINE: Psoriasis, Methotrexate, Dermatologic Agents, Antibodies, Monoclonal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisMethotrexateDermatologic AgentsAntibodies, MonoclonalHumansDouble-Blind MethodFemaleMaleAdultMiddle AgedTreatment OutcomeSeverity of Illness IndexBrazilYoung AdultTime FactorsAged

Stichwörter der Autor:innen

MethotrexatePsoriasisRisankizumab

Substanzen

MethotrexaterisankizumabDermatologic AgentsAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Dermatology, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. Electronic address: tcestari@hcpa.edu.br.
  • Division of Dermatology, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.
  • Instituto de Dermatologia e Estética do Rio de Janeiro, Rio de Janeiro, Brazil.
  • Department of Dermatology, Hospital das Clínicas, Universidade de São Paulo, São Paulo, SP, Brazil.
  • Department of Dermatology, Hospital Moinhos de Vento, Porto Alegre, RS, Brazil.
  • Discipline of Dermatology, Pontifícia Universidade Católica do Paraná, Curitiba, PR, Brazil.

Förderung

  • AbbVie

Zitieren

APA

Cestari, T. F., Souza, C. D. S., Azulay-Abulafia, L., Romiti, R., Carvalho, A. V. E., Silva de Castro, C. C., Marques, S. A., Antonio, J. R., Fabrício, L., Soliman, A. M., Wu, T., Sinvhal, R., Stakias, V., Song, A. P., Kalabic, J., Martin, N., & Oyafuso, L. K. M. (2025). Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil. Anais Brasileiros de Dermatologia. https://doi.org/10.1016/j.abd.2024.08.002

Vancouver

Cestari TF, Souza CDS, Azulay-Abulafia L, Romiti R, Carvalho AVE, Silva de Castro CC, et al. Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil. Anais Brasileiros de Dermatologia. 2025. doi:10.1016/j.abd.2024.08.002

BibTeX
@article{Cestari2025,
  author = {Cestari, Tania F and Souza, Cacilda da Silva and Azulay-Abulafia, Luna and Romiti, Ricardo and Carvalho, André V E and Silva de Castro, Caio César and Marques, Sílvio Alencar and Antonio, João Roberto and Fabrício, Lincoln and Soliman, Ahmed M and Wu, Tianshuang and Sinvhal, Ranjeeta and Stakias, Vassilis and Song, Alexandra P and Kalabic, Jasmina and Martin, Naomi and Oyafuso, Luiza Keiko Matsuka},
  title = {Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil},
  journal = {Anais Brasileiros de Dermatologia},
  year = {2025},
  doi = {10.1016/j.abd.2024.08.002}
}
Kostenlos starten →